Search

Displaying results 6871 - 6880 of 9886 in total
  1. Drug

    FF-10501-01

    go.drugbank.com/drugs/DB17554
    Investigational

    FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer activity. … [A257306] FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome).

  2. Drug

    Nisevokitug

    go.drugbank.com/drugs/DB17561
    Investigational

    Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety

  3. Drug

    DCVax-L

    go.drugbank.com/drugs/DB17580
    Investigational

    DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded _in vitro_ with autologous tumour lysate.

    Synonyms: DCVax-L
  4. Drug

    Ad-CEA vaccine

    go.drugbank.com/drugs/DB17581
    Investigational

    Ad-CEA vaccine is a cancer immunotherapy composed of carcinoembryonic antigen (CEA).

  5. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs).

  6. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]

  7. Drug

    Hemoximer

    go.drugbank.com/drugs/DB17600
    Investigational

    Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.

  8. Drug

    CY-1503

    go.drugbank.com/drugs/DB17605
    Investigational

    CY-1503 is a pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-Dglucopyranosyl unit, and one alpha-L-fucopyranosyl

  9. Drug

    CDX-1135

    go.drugbank.com/drugs/DB17607
    Investigational

    CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex).

  10. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Hunter syndrome is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), which leads to the toxic accumulation of glycosaminoglycans (GAGs) throughout … Tividenofusp alfa is a recombinant human IDS fused to a monoclonal antibody that targets the human insulin receptor (HIR), utilizing receptor-mediated transcytosis to gain access to the central nervous

    Synonyms: -bis(disulfide) with immunoglobulin Fcab anti-(human type 1 transferrin receptor) (synthetic hu, 676>S, L 678>A, Y